Novamind Ventures

Novamind Ventures

Novamind Ventures is a toronto-based psychedelic therapy research and development company founded in 2019 by Yaron Conforti.

Novamind was founded in May 2019 in Toronto, Canada. Ongoing clinical trials approved by the U.S. Food and Drug Administration (“FDA”) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry.

Timeline

March 30, 2020
Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.

Novamind Ventures closed acquisitions of Cedar Psychiatry LLC ("Cedar Psychiatry"),a specialized provider of ketamine-assisted psychotherapy and Cedar Clinical Research LLC ("Cedar Clinical Research"), a dedicated research center focused on psychedelic medicines, both based near Salt Lake City, Utah.

Total consideration paid by Novamind for the Cedar Acquisitions was CAN$3.05 million, consisting of CAN$1 million cash and CAN$2.05 million in Novamind common shares.

May 2019
Novamind Ventures was founded by Yaron Conforti.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.